NEW YORK. (KFSN) -- For decades, doctors have diagnosed prostate cancer using what's been called a 'blind' biopsy, removing and testing a dozen tiny tissue samples to see if cancer is present. Now, ...
SAN FRANCISCO—Prostate cancer (PCa) detection rates may be markedly improved by adding targeted fusion biopsy to conventional blind random biopsies, according to a new study presented at the 37th ...
After a patient has undergone a prostate MRI, the images are sent to radiology to evaluate suspicious lesions. The UroNav fusion biopsy system uses this critical diagnostic information to provide ...
Detection rates of clinically significant cancer, adjusted for age and PSA, improved by 5.2% between cohort 1 and 2 and by an additional 5.2% between cohorts 2 and 3 with fusion biopsy. Among men with ...
In-gantry prostate biopsy of MRI-suspicious regions using real-time magnetic resonance guidance is the gold standard approach to targeted biopsy, but this technique is only available at a few centres ...
TORONTO, Nov. 5, 2019 /PRNewswire-PRWeb/ -- Focal Healthcare, an innovator of image-guided prostate cancer technology, announced it has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy ...
The diagnostics advisory committee considered evidence on MRI fusion biopsy systems using Artemis, Biojet, BiopSee, bkFusion, Fusion Bx 2.0, FusionVu, iSR'obot Mona Lisa, KOELIS Trinity and UroNav ...
GRENOBLE, France and PRINCETON, N.J., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Koelis, SAS (“Koelis” or the “Company”, www.koelis.com), a global leader and innovator in prostate care, announced today the ...
Fusion biopsy systems use MRI and ultrasound together to create a detailed 3D image of the prostate, helping doctors accurately find and target abnormal tissue while guiding the biopsy needle with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback